Gudina Esayas Kebede, Tesfaye Markos, Adane Aynishet, Lemma Kinfe, Shibiru Tamiru, Wieser Andreas, Pfister Hans-Walter, Klein Matthias
Department of Internal Medicine, Jimma University, Jimma, Ethiopia.
Centre for International Health, Ludwig-Maximilians-University, Munich, Germany.
BMC Neurol. 2016 Aug 26;16(1):153. doi: 10.1186/s12883-016-0678-0.
Bacterial meningitis is associated with significant morbidity and mortality despite advances in medical care. The main objective of this study was to assess the association of adjunctive dexamethasone treatment with discharge outcome of patients treated as bacterial meningitis in low income setting.
A retrospective study was conducted at four teaching hospitals across Ethiopia. Patients of age 14 years and older treated as cases of bacterial meningitis between January 1, 2011 and April 30, 2015 were included in this study. Information regarding sociodemographic data, clinical presentations, laboratory data, treatments given and status at hospital discharge were retrieved from patients' medical records using a structured questionnaire. Predefined outcome variables at discharge were analysed using descriptive statistics. Multivariable logistic regression was used to identify factors independently associated with poor outcome.
A total of 425 patients treated with the presumptive clinical diagnosis of bacterial meningitis were included in this study (lumbar puncture done in 56 %; only 19 % had CSF findings compatible with bacterial meningitis, and only 3 % had proven etiology). The overall in hospital mortality rate was 20.2 %. Impaired consciousness, aspiration pneumonia, and cranial nerve palsy at admission were independently associated with increased mortality. Adjuvant dexamethasone, which was used in 50.4 % of patients, was associated with increased in-hospital mortality (AOR = 3.38; 95 % CI 1.87-6.12, p < 0.001) and low Glasgow outcome scale (GOS) at discharge (AOR = 4.46 (95 % CI 1.98-10.08). This association between dexamethasone and unfavorable outcome was found to be more pronounced in suspected but unproven cases and in those without CSF alterations compatible with bacterial meningitis.
Most patients treated for suspected bacterial meningitis did not receive proper diagnostic workup. Adjuvant dexamethasone use in clinically suspected but unproven cases of bacterial meningitis was associated with an increased mortality and poor discharge GOS. These findings show that there are potential deleterious effects in unconfirmed cases in this setting. Physicians practising under such circumstances should thus abide with the current recommendation and defer the use of adjuvant corticosteroid in suspected cases of bacterial meningitis.
尽管医疗水平有所进步,但细菌性脑膜炎仍与较高的发病率和死亡率相关。本研究的主要目的是评估在低收入环境中,辅助使用地塞米松治疗与细菌性脑膜炎患者出院结局之间的关联。
在埃塞俄比亚的四家教学医院开展了一项回顾性研究。纳入2011年1月1日至2015年4月30日期间被当作细菌性脑膜炎病例治疗的14岁及以上患者。使用结构化问卷从患者病历中获取有关社会人口统计学数据、临床表现、实验室数据、所接受治疗及出院时状况的信息。对出院时预先定义的结局变量进行描述性统计分析。采用多变量逻辑回归来确定与不良结局独立相关的因素。
本研究共纳入425例临床疑似细菌性脑膜炎的患者(56%进行了腰椎穿刺;仅19%的脑脊液检查结果符合细菌性脑膜炎,仅3%有确诊病因)。总体院内死亡率为20.2%。入院时意识障碍、吸入性肺炎和脑神经麻痹与死亡率增加独立相关。50.4%的患者使用了辅助地塞米松,其与院内死亡率增加(比值比[AOR]=3.38;95%置信区间[CI]1.87 - 6.12,p<0.001)及出院时低格拉斯哥结局量表(GOS)评分相关(AOR=4.46[95%CI 1.98 - 10.08])。在地塞米松与不良结局之间的这种关联在疑似但未确诊的病例以及脑脊液检查结果与细菌性脑膜炎不符的病例中更为明显。
大多数因疑似细菌性脑膜炎接受治疗的患者未接受适当的诊断检查。在临床疑似但未确诊的细菌性脑膜炎病例中使用辅助地塞米松与死亡率增加及出院时GOS评分低相关。这些发现表明,在这种情况下,未确诊病例存在潜在有害影响。因此,在这种情况下执业的医生应遵循当前建议,在疑似细菌性脑膜炎病例中推迟使用辅助性皮质类固醇。